Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers World Congress 2017

David Wong's Biography



David Wong, Felix and Mildred Yip Endowed Chair in Dentistry; Director for UCLA Center for Oral/Head & Neck Oncology Research, University of California-Los Angeles

David T.W. Wong DMD, DMSc is Felix & Mildred Yip Endowed Professor, Associate Dean of Research and Director of the Oral/Head and Neck Oncology Research Center at UCLA. Dr. Wong is an active scientist in oral cancer and saliva diagnostics research. He has authored over 280 peer reviewed scientific publications. He is a fellow of the American Association for the Advancement of Sciences (AAAS), past member of the ADA Council of Scientific Affairs and the past president of American Association of Dental Research (AADR).

David Wong Image

Saliva Liquid Biopsy (sLB)

Monday, 20 March 2017 at 11:45

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Liquid biopsy is a rapidly emerging field to address this unmet clinical need as diagnostics based on cell-free circulating tumor DNA (ctDNA) can be a surrogate for the entire tumor genome. The use of ctDNA via liquid biopsy will facilitate analysis of tumor genomics that is urgently needed for molecular targeted therapy. Currently, most targeted approaches are based on PCR and/or next generation sequencing (NGS) for liquid biopsy applications with performance concordance in the 70-80% range with biopsy-based genotyping.  “Electric Field Induced Release and Measurement (EFIRM)” is an emerging liquid biopsy technology that provides the most accurate detection that can assist clinical treatment decisions for the most common subtype of lung cancer, non-small cell lung cancer (NSCLC), with tyrosine kinase inhibitors (TKI) that can extend the disease progress free survival period of these patients. EFIRM can detection ctDNA at single copy level whereas ddPCR detects ctDNA a minimum of 10 copy number. In addition EFIRM requires only 40 µl of sample volume, no sample processing, reaction time is 15min and can be performed at the point-of-care or high throughput reference lab using plasma or saliva. In two blinded independent clinical studies, EFIRM detects actionable EGFR mutations in NSCLC patients with >95% concordance with biopsy-based genotyping. EFIRM is minimally/ non-invasive detecting the most common EGFR gene mutations that are treatable with TKI such as Gefitinib or Erlotinib to effectively extend the progression free survival of lung cancer patients.

Saliva Liquid Biopsy (sLB)

Monday, 20 March 2017 at 11:45

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Liquid biopsy is a rapidly emerging field to address this unmet clinical need as diagnostics based on cell-free circulating tumor DNA (ctDNA) can be a surrogate for the entire tumor genome. The use of ctDNA via liquid biopsy will facilitate analysis of tumor genomics that is urgently needed for molecular targeted therapy. Currently, most targeted approaches are based on PCR and/or next generation sequencing (NGS) for liquid biopsy applications with performance concordance in the 70-80% range with biopsy-based genotyping.  “Electric Field Induced Release and Measurement (EFIRM)” is an emerging liquid biopsy technology that provides the most accurate detection that can assist clinical treatment decisions for the most common subtype of lung cancer, non-small cell lung cancer (NSCLC), with tyrosine kinase inhibitors (TKI) that can extend the disease progress free survival period of these patients. EFIRM can detection ctDNA at single copy level whereas ddPCR detects ctDNA a minimum of 10 copy number. In addition EFIRM requires only 40 µl of sample volume, no sample processing, reaction time is 15min and can be performed at the point-of-care or high throughput reference lab using plasma or saliva. In two blinded independent clinical studies, EFIRM detects actionable EGFR mutations in NSCLC patients with >95% concordance with biopsy-based genotyping. EFIRM is minimally/ non-invasive detecting the most common EGFR gene mutations that are treatable with TKI such as Gefitinib or Erlotinib to effectively extend the progression free survival of lung cancer patients.


Add to Calendar ▼2017-03-20 00:00:002017-03-21 00:00:00Europe/LondonCirculating Biomarkers World Congress 2017Circulating Biomarkers World Congress 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com